Skip to main content
Top
Published in: Critical Care 1/2016

Open Access 01-12-2016 | Review

Ebola virus disease and critical illness

Authors: Aleksandra Leligdowicz, William A. Fischer II, Timothy M. Uyeki, Thomas E. Fletcher, Neill K. J. Adhikari, Gina Portella, Francois Lamontagne, Christophe Clement, Shevin T. Jacob, Lewis Rubinson, Abel Vanderschuren, Jan Hajek, Srinivas Murthy, Mauricio Ferri, Ian Crozier, Elhadj Ibrahima, Marie-Claire Lamah, John S. Schieffelin, David Brett-Major, Daniel G. Bausch, Nikki Shindo, Adrienne K. Chan, Tim O’Dempsey, Sharmistha Mishra, Michael Jacobs, Stuart Dickson, G. Marshall Lyon III, Robert A. Fowler

Published in: Critical Care | Issue 1/2016

Login to get access

Abstract

As of 20 May 2016 there have been 28,646 cases and 11,323 deaths resulting from the West African Ebola virus disease (EVD) outbreak reported to the World Health Organization. There continue to be sporadic flare-ups of EVD cases in West Africa.
EVD presentation is nonspecific and characterized initially by onset of fatigue, myalgias, arthralgias, headache, and fever; this is followed several days later by anorexia, nausea, vomiting, diarrhea, and abdominal pain. Anorexia and gastrointestinal losses lead to dehydration, electrolyte abnormalities, and metabolic acidosis, and, in some patients, acute kidney injury. Hypoxia and ventilation failure occurs most often with severe illness and may be exacerbated by substantial fluid requirements for intravascular volume repletion and some degree of systemic capillary leak. Although minor bleeding manifestations are common, hypovolemic and septic shock complicated by multisystem organ dysfunction appear the most frequent causes of death.
Males and females have been equally affected, with children (0–14 years of age) accounting for 19 %, young adults (15–44 years) 58 %, and older adults (≥45 years) 23 % of reported cases. While the current case fatality proportion in West Africa is approximately 40 %, it has varied substantially over time (highest near the outbreak onset) according to available resources (40–90 % mortality in West Africa compared to under 20 % in Western Europe and the USA), by age (near universal among neonates and high among older adults), and by Ebola viral load at admission.
While there is no Ebola virus-specific therapy proven to be effective in clinical trials, mortality has been dramatically lower among EVD patients managed with supportive intensive care in highly resourced settings, allowing for the avoidance of hypovolemia, correction of electrolyte and metabolic abnormalities, and the provision of oxygen, ventilation, vasopressors, and dialysis when indicated. This experience emphasizes that, in addition to evaluating specific medical treatments, improving the global capacity to provide supportive critical care to patients with EVD may be the greatest opportunity to improve patient outcomes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med. 2014;371(15):1418–25.PubMedCrossRef Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med. 2014;371(15):1418–25.PubMedCrossRef
2.
go back to reference Bres P. The epidemic of Ebola haemorrhagic fever in Sudan and Zaire, 1976: introductory note. Bull World Health Organ. 1978;56(2):245.PubMedPubMedCentral Bres P. The epidemic of Ebola haemorrhagic fever in Sudan and Zaire, 1976: introductory note. Bull World Health Organ. 1978;56(2):245.PubMedPubMedCentral
5.
go back to reference Bah EI, Lamah MC, Fletcher T, et al. Clinical presentation of patients with Ebola virus disease in Conakry. Guinea N Engl J Med. 2015;372(1):40–7.PubMedCrossRef Bah EI, Lamah MC, Fletcher T, et al. Clinical presentation of patients with Ebola virus disease in Conakry. Guinea N Engl J Med. 2015;372(1):40–7.PubMedCrossRef
6.
go back to reference Schieffelin JS, Shaffer JG, Goba A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014;371(22):2092–100.PubMedPubMedCentralCrossRef Schieffelin JS, Shaffer JG, Goba A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014;371(22):2092–100.PubMedPubMedCentralCrossRef
7.
go back to reference Fauci AS. Ebola—underscoring the global disparities in health care resources. N Engl J Med. 2014;371(12):1084–6.PubMedCrossRef Fauci AS. Ebola—underscoring the global disparities in health care resources. N Engl J Med. 2014;371(12):1084–6.PubMedCrossRef
8.
go back to reference Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis. 2011;204 Suppl 3:S810–6.PubMedCrossRef Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis. 2011;204 Suppl 3:S810–6.PubMedCrossRef
9.
go back to reference Bwaka MA, Bonnet MJ, Calain P, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis. 1999;179 Suppl 1:S1–7.PubMedCrossRef Bwaka MA, Bonnet MJ, Calain P, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis. 1999;179 Suppl 1:S1–7.PubMedCrossRef
10.
go back to reference Peters CJ, LeDuc JW. An introduction to Ebola: the virus and the disease. J Infect Dis. 1999;179 Suppl 1:ix–xvi.PubMed Peters CJ, LeDuc JW. An introduction to Ebola: the virus and the disease. J Infect Dis. 1999;179 Suppl 1:ix–xvi.PubMed
11.
go back to reference WHO. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978;56(2):271–93. WHO. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978;56(2):271–93.
12.
go back to reference WHO. Ebola haemorrhagic fever in Sudan, 1976 Report of a WHO/International Study Team. Bull World Health Organ. 1978;56(2):247–70. WHO. Ebola haemorrhagic fever in Sudan, 1976 Report of a WHO/International Study Team. Bull World Health Organ. 1978;56(2):247–70.
13.
go back to reference Gire SK, Goba A, Andersen KG, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science. 2014;345(6202):1369–72.PubMedPubMedCentralCrossRef Gire SK, Goba A, Andersen KG, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science. 2014;345(6202):1369–72.PubMedPubMedCentralCrossRef
16.
go back to reference Team WHOER. Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371(16):1481–95.CrossRef Team WHOER. Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371(16):1481–95.CrossRef
17.
go back to reference Victory KR, Coronado F, Ifono SO, et al. Ebola transmission linked to a single traditional funeral ceremony—Kissidougou, Guinea, December, 2014-January 2015. MMWR Morb Mortal Wkly Rep. 2015;64(14):386–8.PubMed Victory KR, Coronado F, Ifono SO, et al. Ebola transmission linked to a single traditional funeral ceremony—Kissidougou, Guinea, December, 2014-January 2015. MMWR Morb Mortal Wkly Rep. 2015;64(14):386–8.PubMed
18.
go back to reference WHO. Interim infection prevention and control guidance for care of patients with suspected or confirmed filovirus haemorrhagic fever in health-care settings, with focus on Ebola. Geneva, Switzerland: WHO; 2014. WHO. Interim infection prevention and control guidance for care of patients with suspected or confirmed filovirus haemorrhagic fever in health-care settings, with focus on Ebola. Geneva, Switzerland: WHO; 2014.
19.
go back to reference Johnson E, Jaax N, White J, et al. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol. 1995;76(4):227–36.PubMedPubMedCentral Johnson E, Jaax N, White J, et al. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol. 1995;76(4):227–36.PubMedPubMedCentral
20.
go back to reference Jaax N, Jahrling P, Geisbert T, et al. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet. 1995;346(8991-8992):1669–71.PubMedCrossRef Jaax N, Jahrling P, Geisbert T, et al. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet. 1995;346(8991-8992):1669–71.PubMedCrossRef
21.
go back to reference Brearley MB, Heaney MF, Norton IN. Physiological responses of medical team members to a simulated emergency in tropical field conditions. Prehosp Disaster Med. 2013;28(2):139–44.PubMedCrossRef Brearley MB, Heaney MF, Norton IN. Physiological responses of medical team members to a simulated emergency in tropical field conditions. Prehosp Disaster Med. 2013;28(2):139–44.PubMedCrossRef
22.
go back to reference WHO. Health worker Ebola infections in Guinea, Liberia and Sierra Leone. Geneva, Switzerland: WHO; 2015. WHO. Health worker Ebola infections in Guinea, Liberia and Sierra Leone. Geneva, Switzerland: WHO; 2015.
23.
go back to reference Suwantarat N, Apisarnthanarak A. Risks to healthcare workers with emerging diseases: lessons from MERS-CoV, Ebola, SARS, and avian flu. Curr Opin Infect Dis. 2015;28(4):349–61.PubMedCrossRef Suwantarat N, Apisarnthanarak A. Risks to healthcare workers with emerging diseases: lessons from MERS-CoV, Ebola, SARS, and avian flu. Curr Opin Infect Dis. 2015;28(4):349–61.PubMedCrossRef
24.
go back to reference Lopaz MA, Amela C, Ordobas M, et al. First secondary case of Ebola outside Africa: epidemiological characteristics and contact monitoring, Spain, September to November 2014. Euro Surveill. 2015;20(1). Lopaz MA, Amela C, Ordobas M, et al. First secondary case of Ebola outside Africa: epidemiological characteristics and contact monitoring, Spain, September to November 2014. Euro Surveill. 2015;20(1).
25.
go back to reference Mora-Rillo M, Arsuaga M, Ramirez-Olivencia G, et al. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid. Spain Lancet Respir Med. 2015;3(7):554–62.PubMedCrossRef Mora-Rillo M, Arsuaga M, Ramirez-Olivencia G, et al. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid. Spain Lancet Respir Med. 2015;3(7):554–62.PubMedCrossRef
26.
go back to reference Chevalier MS, Chung W, Smith J, et al. Ebola virus disease cluster in the United States—Dallas County, Texas, 2014. MMWR Morb Mortal Wkly Rep. 2014;63(46):1087–8.PubMed Chevalier MS, Chung W, Smith J, et al. Ebola virus disease cluster in the United States—Dallas County, Texas, 2014. MMWR Morb Mortal Wkly Rep. 2014;63(46):1087–8.PubMed
27.
go back to reference Tartari E, Allegranzi B, Ang B, et al. Preparedness of institutions around the world for managing patients with Ebola virus disease: an infection control readiness checklist. Antimicrob Resist Infect Control. 2015;4:22.PubMedPubMedCentralCrossRef Tartari E, Allegranzi B, Ang B, et al. Preparedness of institutions around the world for managing patients with Ebola virus disease: an infection control readiness checklist. Antimicrob Resist Infect Control. 2015;4:22.PubMedPubMedCentralCrossRef
28.
go back to reference Johnson DW, Sullivan JN, Piquette CA, et al. Lessons learned: critical care management of patients with Ebola in the United States. Crit Care Med. 2015;43(6):1157–64.PubMedCrossRef Johnson DW, Sullivan JN, Piquette CA, et al. Lessons learned: critical care management of patients with Ebola in the United States. Crit Care Med. 2015;43(6):1157–64.PubMedCrossRef
29.
go back to reference McElroy AK, Erickson BR, Flietstra TD, et al. Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. J Infect Dis. 2014;210(4):558–66.PubMedPubMedCentralCrossRef McElroy AK, Erickson BR, Flietstra TD, et al. Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. J Infect Dis. 2014;210(4):558–66.PubMedPubMedCentralCrossRef
30.
go back to reference Fletcher TE, Fowler RA, Beeching NJ. Understanding organ dysfunction in Ebola virus disease. Intensive Care Med. 2014;40(12):1936–9.PubMedCrossRef Fletcher TE, Fowler RA, Beeching NJ. Understanding organ dysfunction in Ebola virus disease. Intensive Care Med. 2014;40(12):1936–9.PubMedCrossRef
32.
go back to reference Martin P, Laupland KB, Frost EH, et al. Laboratory diagnosis of Ebola virus disease. Intensive Care Med. 2015;41(5):895–8.PubMedCrossRef Martin P, Laupland KB, Frost EH, et al. Laboratory diagnosis of Ebola virus disease. Intensive Care Med. 2015;41(5):895–8.PubMedCrossRef
33.
go back to reference WHO. Clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line health worker. Geneva, Switzerland: WHO; 2014. WHO. Clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line health worker. Geneva, Switzerland: WHO; 2014.
34.
go back to reference Broadhurst MJ, Kelly JD, Miller A, et al. ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study. Lancet. 2015;386(9996):867–74.PubMedCrossRef Broadhurst MJ, Kelly JD, Miller A, et al. ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study. Lancet. 2015;386(9996):867–74.PubMedCrossRef
36.
go back to reference Nkoghe D, Leroy EM, Toung-Mve M, et al. Cutaneous manifestations of filovirus infections. Int J Dermatol. 2012;51(9):1037–43.PubMedCrossRef Nkoghe D, Leroy EM, Toung-Mve M, et al. Cutaneous manifestations of filovirus infections. Int J Dermatol. 2012;51(9):1037–43.PubMedCrossRef
37.
go back to reference Schibler M, Vetter P, Cherpillod P, et al. Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report. Lancet Infect Dis. 2015;15(9):1034–40.PubMedCrossRef Schibler M, Vetter P, Cherpillod P, et al. Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report. Lancet Infect Dis. 2015;15(9):1034–40.PubMedCrossRef
38.
go back to reference Wolf T, Kann G, Becker S, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet. 2015;385(9976):1428–35.PubMedCrossRef Wolf T, Kann G, Becker S, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet. 2015;385(9976):1428–35.PubMedCrossRef
39.
go back to reference Khan AS, Tshioko FK, Heymann DL, et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis. 1999;179 Suppl 1:S76–86.PubMedCrossRef Khan AS, Tshioko FK, Heymann DL, et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis. 1999;179 Suppl 1:S76–86.PubMedCrossRef
40.
go back to reference Uyeki TM, Mehta AK, Davey RT Jr, Liddell AM, Wolf T, Vetter P, Schmiedel S, Grünewald T, Jacobs M, Arribas JR, Evans L, Hewlett AL, Brantsaeter AB, Ippolito G, Rapp C, Hoepelman AI, Gutman J; Working Group of the U.S.–European Clinical Network on Clinical Management of Ebola Virus Disease Patients in the U.S. and Europe. Clinical Management of Ebola Virus Disease in the United States and Europe. N Engl J Med. 2016;18;374(7):636–46. Uyeki TM, Mehta AK, Davey RT Jr, Liddell AM, Wolf T, Vetter P, Schmiedel S, Grünewald T, Jacobs M, Arribas JR, Evans L, Hewlett AL, Brantsaeter AB, Ippolito G, Rapp C, Hoepelman AI, Gutman J; Working Group of the U.S.–European Clinical Network on Clinical Management of Ebola Virus Disease Patients in the U.S. and Europe. Clinical Management of Ebola Virus Disease in the United States and Europe. N Engl J Med. 2016;18;374(7):636–46.
41.
go back to reference Chertow DS, Kleine C, Edwards JK, et al. Ebola virus disease in West Africa—clinical manifestations and management. N Engl J Med. 2014;371(22):2054–7.PubMedCrossRef Chertow DS, Kleine C, Edwards JK, et al. Ebola virus disease in West Africa—clinical manifestations and management. N Engl J Med. 2014;371(22):2054–7.PubMedCrossRef
42.
go back to reference Kreuels B, Wichmann D, Emmerich P, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med. 2014;371(25):2394–401.PubMedCrossRef Kreuels B, Wichmann D, Emmerich P, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med. 2014;371(25):2394–401.PubMedCrossRef
43.
go back to reference Fitzpatrick G, Vogt F, Moi Gbabai OB, et al. The contribution of Ebola viral load at admission and other patient characteristics to mortality in a Medecins Sans Frontieres Ebola Case Management Centre, Kailahun, Sierra Leone, June–October 2014. J Infect Dis. 2015;212(11):1752–8.PubMedPubMedCentralCrossRef Fitzpatrick G, Vogt F, Moi Gbabai OB, et al. The contribution of Ebola viral load at admission and other patient characteristics to mortality in a Medecins Sans Frontieres Ebola Case Management Centre, Kailahun, Sierra Leone, June–October 2014. J Infect Dis. 2015;212(11):1752–8.PubMedPubMedCentralCrossRef
44.
go back to reference Mupapa K, Mukundu W, Bwaka MA, et al. Ebola hemorrhagic fever and pregnancy. J Infect Dis. 1999;179 Suppl 1:S11–12.PubMedCrossRef Mupapa K, Mukundu W, Bwaka MA, et al. Ebola hemorrhagic fever and pregnancy. J Infect Dis. 1999;179 Suppl 1:S11–12.PubMedCrossRef
45.
go back to reference Towner JS, Rollin PE, Bausch DG, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol. 2004;78(8):4330–41.PubMedPubMedCentralCrossRef Towner JS, Rollin PE, Bausch DG, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol. 2004;78(8):4330–41.PubMedPubMedCentralCrossRef
46.
go back to reference Faye O, Andronico A, Faye O, et al. Use of viremia to evaluate the baseline case fatality ratio of Ebola virus disease and inform treatment studies: a retrospective cohort study. PLoS Med. 2015;12(12):e1001908.PubMedPubMedCentralCrossRef Faye O, Andronico A, Faye O, et al. Use of viremia to evaluate the baseline case fatality ratio of Ebola virus disease and inform treatment studies: a retrospective cohort study. PLoS Med. 2015;12(12):e1001908.PubMedPubMedCentralCrossRef
48.
go back to reference Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis. 2007;196 Suppl 2:S364–371.PubMedCrossRef Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis. 2007;196 Suppl 2:S364–371.PubMedCrossRef
49.
go back to reference Fowler RA, Fletcher T. Fischer 2nd WA, et al. Caring for critically ill patients with Ebola virus disease. Perspectives from West Africa. Am J Respir Crit Care Med. 2014;190(7):733–7.PubMedCrossRef Fowler RA, Fletcher T. Fischer 2nd WA, et al. Caring for critically ill patients with Ebola virus disease. Perspectives from West Africa. Am J Respir Crit Care Med. 2014;190(7):733–7.PubMedCrossRef
50.
go back to reference West TE. von Saint Andre-von Arnim A. Clinical presentation and management of severe Ebola virus disease. Ann Am Thorac Soc. 2014;11(9):1341–50.PubMedCrossRef West TE. von Saint Andre-von Arnim A. Clinical presentation and management of severe Ebola virus disease. Ann Am Thorac Soc. 2014;11(9):1341–50.PubMedCrossRef
51.
go back to reference Cellarier GR, Bordes J, Karkowski L, et al. Safety, feasibility, and interest of transthoracic echocardiography in a deployed French military Ebola virus disease treatment center in Guinea. Intensive Care Med. 2015;41(8):1491–2.PubMedCrossRef Cellarier GR, Bordes J, Karkowski L, et al. Safety, feasibility, and interest of transthoracic echocardiography in a deployed French military Ebola virus disease treatment center in Guinea. Intensive Care Med. 2015;41(8):1491–2.PubMedCrossRef
52.
go back to reference Auffermann WF, Kraft CS, Vanairsdale S, et al. Radiographic imaging for patients with contagious infectious diseases: how to acquire chest radiographs of patients infected with the Ebola virus. AJR Am J Roentgenol. 2015;204(1):44–8.PubMedCrossRef Auffermann WF, Kraft CS, Vanairsdale S, et al. Radiographic imaging for patients with contagious infectious diseases: how to acquire chest radiographs of patients infected with the Ebola virus. AJR Am J Roentgenol. 2015;204(1):44–8.PubMedCrossRef
53.
go back to reference Bausch DG, Towner JS, Dowell SF, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis. 2007;196 Suppl 2:S142–7.PubMedCrossRef Bausch DG, Towner JS, Dowell SF, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis. 2007;196 Suppl 2:S142–7.PubMedCrossRef
54.
go back to reference Formenty P, Leroy EM, Epelboin A, et al. Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo. Clin Infect Dis. 2006;42(11):1521–6.PubMedCrossRef Formenty P, Leroy EM, Epelboin A, et al. Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo. Clin Infect Dis. 2006;42(11):1521–6.PubMedCrossRef
55.
go back to reference Zaki SR, Shieh WJ, Greer PW, et al. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis. 1999;179 Suppl 1:S36–47.PubMedCrossRef Zaki SR, Shieh WJ, Greer PW, et al. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis. 1999;179 Suppl 1:S36–47.PubMedCrossRef
56.
go back to reference Rowe AK, Bertolli J, Khan AS, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis. 1999;179 Suppl 1:S28–35.PubMedCrossRef Rowe AK, Bertolli J, Khan AS, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis. 1999;179 Suppl 1:S28–35.PubMedCrossRef
57.
go back to reference Rodriguez LL, De Roo A, Guimard Y, et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis. 1999;179 Suppl 1:S170–6.PubMedCrossRef Rodriguez LL, De Roo A, Guimard Y, et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis. 1999;179 Suppl 1:S170–6.PubMedCrossRef
58.
59.
go back to reference Deen GF, Knust B, Broutet N, et al. Ebola RNA persistence in semen of Ebola virus disease survivors—preliminary report. N Engl J Med. 2015. doi:10.1056/NEJMoa1511410, http://www.nejm.org/doi/pdf/10.1056/NEJMoa1511410. Deen GF, Knust B, Broutet N, et al. Ebola RNA persistence in semen of Ebola virus disease survivors—preliminary report. N Engl J Med. 2015. doi:10.​1056/​NEJMoa1511410, http://​www.​nejm.​org/​doi/​pdf/​10.​1056/​NEJMoa1511410.​
61.
go back to reference Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A, Gifford RJ, Hopkins S, Hughes J, Jabeen F, Johannessen I, Karageorgopoulos D, Lackenby A, Lester R, Liu RS, MacConnachie A, Mahungu T, Martin D, Marshall N, Mepham S, Orton R, Palmarini M, Patel M, Perry C, Peters SE, Porter D, Ritchie D, Ritchie ND, Seaton RA, Sreenu VB, Templeton K, Warren S, Wilkie GS, Zambon M, Gopal R, Thomson EC. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet. 2016 May 18. pii: S0140–6736(16)30386-5. doi:10.1016/S0140-6736(16)30386-5. [Epub ahead of print]. Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A, Gifford RJ, Hopkins S, Hughes J, Jabeen F, Johannessen I, Karageorgopoulos D, Lackenby A, Lester R, Liu RS, MacConnachie A, Mahungu T, Martin D, Marshall N, Mepham S, Orton R, Palmarini M, Patel M, Perry C, Peters SE, Porter D, Ritchie D, Ritchie ND, Seaton RA, Sreenu VB, Templeton K, Warren S, Wilkie GS, Zambon M, Gopal R, Thomson EC. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet. 2016 May 18. pii: S0140–6736(16)30386-5. doi:10.​1016/​S0140-6736(16)30386-5. [Epub ahead of print].
65.
66.
go back to reference Maitland K, Kiguli S, Opoka RO, et al. Mortality after fluid bolus in African children with severe infection. N Engl J Med. 2011;364(26):2483–95.PubMedCrossRef Maitland K, Kiguli S, Opoka RO, et al. Mortality after fluid bolus in African children with severe infection. N Engl J Med. 2011;364(26):2483–95.PubMedCrossRef
67.
go back to reference Andrews B, Muchemwa L, Kelly P, et al. Simplified severe sepsis protocol: a randomized controlled trial of modified early goal-directed therapy in Zambia. Crit Care Med. 2014;42(11):2315–24.PubMedPubMedCentralCrossRef Andrews B, Muchemwa L, Kelly P, et al. Simplified severe sepsis protocol: a randomized controlled trial of modified early goal-directed therapy in Zambia. Crit Care Med. 2014;42(11):2315–24.PubMedPubMedCentralCrossRef
68.
go back to reference Kortepeter MG, Lawler JV, Honko A, et al. Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus. J Infect Dis. 2011;204 Suppl 3:S1000–10.PubMedCrossRef Kortepeter MG, Lawler JV, Honko A, et al. Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus. J Infect Dis. 2011;204 Suppl 3:S1000–10.PubMedCrossRef
69.
go back to reference Roberts I, Perner A. Ebola virus disease: clinical care and patient-centred research. Lancet. 2014;384(9959):2001–2.PubMedCrossRef Roberts I, Perner A. Ebola virus disease: clinical care and patient-centred research. Lancet. 2014;384(9959):2001–2.PubMedCrossRef
70.
go back to reference Perner A, Fowler RA, Bellomo R, et al. Ebola care and research protocols. Intensive Care Med. 2015;41(1):111–4.PubMedCrossRef Perner A, Fowler RA, Bellomo R, et al. Ebola care and research protocols. Intensive Care Med. 2015;41(1):111–4.PubMedCrossRef
72.
go back to reference Rees PS, Lamb LE, Nicholson-Roberts TC, et al. Safety and feasibility of a strategy of early central venous catheter insertion in a deployed UK military Ebola virus disease treatment unit. Intensive Care Med. 2015;41(5):735–43.PubMedCrossRef Rees PS, Lamb LE, Nicholson-Roberts TC, et al. Safety and feasibility of a strategy of early central venous catheter insertion in a deployed UK military Ebola virus disease treatment unit. Intensive Care Med. 2015;41(5):735–43.PubMedCrossRef
73.
go back to reference Paterson ML, Callahan CW. The use of intraosseous fluid resuscitation in a pediatric patient with Ebola virus disease. J Emerg Med. 2015;49(6):962–4.PubMedCrossRef Paterson ML, Callahan CW. The use of intraosseous fluid resuscitation in a pediatric patient with Ebola virus disease. J Emerg Med. 2015;49(6):962–4.PubMedCrossRef
74.
go back to reference Lamontagne F, Clement C, Fletcher T, et al. Doing today’s work superbly well—treating Ebola with current tools. N Engl J Med. 2014;371(17):1565–6.PubMedCrossRef Lamontagne F, Clement C, Fletcher T, et al. Doing today’s work superbly well—treating Ebola with current tools. N Engl J Med. 2014;371(17):1565–6.PubMedCrossRef
75.
go back to reference Murthy S. Ebola Clinical Care authors group. Ebola and provision of critical care. Lancet. 2015;385(9976):1392–3.PubMedCrossRef Murthy S. Ebola Clinical Care authors group. Ebola and provision of critical care. Lancet. 2015;385(9976):1392–3.PubMedCrossRef
76.
go back to reference Lyon GM, Mehta AK, Varkey JB, et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med. 2014;371(25):2402–9.PubMedCrossRef Lyon GM, Mehta AK, Varkey JB, et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med. 2014;371(25):2402–9.PubMedCrossRef
77.
go back to reference Parra JM, Salmeron OJ, Velasco M. The first case of Ebola virus disease acquired outside Africa. N Engl J Med. 2014;371(25):2439–40.PubMedCrossRef Parra JM, Salmeron OJ, Velasco M. The first case of Ebola virus disease acquired outside Africa. N Engl J Med. 2014;371(25):2439–40.PubMedCrossRef
78.
go back to reference Connor Jr MJ, Kraft C, Mehta AK, et al. Successful delivery of RRT in Ebola virus disease. J Am Soc Nephrol. 2015;26(1):31–7.PubMedCrossRef Connor Jr MJ, Kraft C, Mehta AK, et al. Successful delivery of RRT in Ebola virus disease. J Am Soc Nephrol. 2015;26(1):31–7.PubMedCrossRef
79.
go back to reference Kraft CS, Hewlett AL, Koepsell S, et al. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis. 2015;61(4):496–502.PubMedCrossRef Kraft CS, Hewlett AL, Koepsell S, et al. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis. 2015;61(4):496–502.PubMedCrossRef
80.
go back to reference Rubin EJ, Baden LR. Out of Africa—caring for patients with Ebola. N Engl J Med. 2014;371(25):2430–2.PubMedCrossRef Rubin EJ, Baden LR. Out of Africa—caring for patients with Ebola. N Engl J Med. 2014;371(25):2430–2.PubMedCrossRef
81.
go back to reference Liddell AM, Davey Jr RT, Mehta AK, et al. Characteristics and clinical management of a cluster of 3 patients with Ebola virus disease, including the first domestically acquired cases in the United States. Ann Intern Med. 2015;163(2):81–90.PubMedPubMedCentralCrossRef Liddell AM, Davey Jr RT, Mehta AK, et al. Characteristics and clinical management of a cluster of 3 patients with Ebola virus disease, including the first domestically acquired cases in the United States. Ann Intern Med. 2015;163(2):81–90.PubMedPubMedCentralCrossRef
82.
go back to reference Sueblinvong V, Johnson DW, Weinstein GL, et al. Critical care for multiple organ failure secondary to Ebola virus disease in the United States. Crit Care Med. 2015;43(10):2066–75.PubMedPubMedCentralCrossRef Sueblinvong V, Johnson DW, Weinstein GL, et al. Critical care for multiple organ failure secondary to Ebola virus disease in the United States. Crit Care Med. 2015;43(10):2066–75.PubMedPubMedCentralCrossRef
83.
go back to reference Stephens DS, Ribner BS, Gartland BD, et al. Ebola virus disease: experience and decision making for the first patients outside of Africa. PLoS Med. 2015;12(7):e1001857.PubMedPubMedCentralCrossRef Stephens DS, Ribner BS, Gartland BD, et al. Ebola virus disease: experience and decision making for the first patients outside of Africa. PLoS Med. 2015;12(7):e1001857.PubMedPubMedCentralCrossRef
84.
go back to reference Boggild AK, Esposito DH, Kozarsky PE, et al. Differential diagnosis of illness in travelers arriving from Sierra Leone, Liberia, or Guinea: a cross-sectional study from the GeoSentinel Surveillance Network. Ann Intern Med. 2015;162(11):757–64.PubMedPubMedCentralCrossRef Boggild AK, Esposito DH, Kozarsky PE, et al. Differential diagnosis of illness in travelers arriving from Sierra Leone, Liberia, or Guinea: a cross-sectional study from the GeoSentinel Surveillance Network. Ann Intern Med. 2015;162(11):757–64.PubMedPubMedCentralCrossRef
85.
go back to reference Tan KR, Cullen KA, Koumans EH, et al. Inadequate diagnosis and treatment of malaria among travelers returning from Africa during the Ebola epidemic—United States, 2014–2015. MMWR Morb Mortal Wkly Rep. 2016;65(2):27–9.PubMedCrossRef Tan KR, Cullen KA, Koumans EH, et al. Inadequate diagnosis and treatment of malaria among travelers returning from Africa during the Ebola epidemic—United States, 2014–2015. MMWR Morb Mortal Wkly Rep. 2016;65(2):27–9.PubMedCrossRef
86.
go back to reference Decker BK, Sevransky JE, Barrett K, et al. Preparing for critical care services to patients with Ebola. Ann Intern Med. 2014;161(11):831–2.PubMedCrossRef Decker BK, Sevransky JE, Barrett K, et al. Preparing for critical care services to patients with Ebola. Ann Intern Med. 2014;161(11):831–2.PubMedCrossRef
87.
go back to reference Halpern SD, Emanuel EJ. Ethical guidance on the use of life-sustaining therapies for patients with Ebola in developed countries. Ann Intern Med. 2015;162(4):304–5.PubMedCrossRef Halpern SD, Emanuel EJ. Ethical guidance on the use of life-sustaining therapies for patients with Ebola in developed countries. Ann Intern Med. 2015;162(4):304–5.PubMedCrossRef
88.
go back to reference Torabi-Parizi P, Davey Jr RT, Suffredini AF, et al. Ethical and practical considerations in providing critical care to patients with Ebola virus disease. Chest. 2015;147(6):1460–6.PubMedPubMedCentralCrossRef Torabi-Parizi P, Davey Jr RT, Suffredini AF, et al. Ethical and practical considerations in providing critical care to patients with Ebola virus disease. Chest. 2015;147(6):1460–6.PubMedPubMedCentralCrossRef
90.
91.
go back to reference Bishop BM. Potential and emerging treatment options for Ebola virus disease. Ann Pharmacother. 2015;49(2):196–206.PubMedCrossRef Bishop BM. Potential and emerging treatment options for Ebola virus disease. Ann Pharmacother. 2015;49(2):196–206.PubMedCrossRef
93.
go back to reference WHO. Potential new Ebola therapies and vaccines. Geneva, Switzerland: WHO; 2014. WHO. Potential new Ebola therapies and vaccines. Geneva, Switzerland: WHO; 2014.
97.
go back to reference Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016;13(3):e1001967.PubMedPubMedCentralCrossRef Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016;13(3):e1001967.PubMedPubMedCentralCrossRef
98.
go back to reference Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis. 1999;179 Suppl 1:S18–23.PubMedCrossRef Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis. 1999;179 Suppl 1:S18–23.PubMedCrossRef
99.
go back to reference Florescu DF, Kalil AC, Hewlett AL, et al. Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease. Clin Infect Dis. 2015;61(6):969–73.PubMedCrossRef Florescu DF, Kalil AC, Hewlett AL, et al. Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease. Clin Infect Dis. 2015;61(6):969–73.PubMedCrossRef
100.
go back to reference Takada A, Ebihara H, Jones S, et al. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine. 2007;25(6):993–9.PubMedCrossRef Takada A, Ebihara H, Jones S, et al. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine. 2007;25(6):993–9.PubMedCrossRef
101.
go back to reference Marzi A, Yoshida R, Miyamoto H, et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One. 2012;7(4):e36192.PubMedPubMedCentralCrossRef Marzi A, Yoshida R, Miyamoto H, et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One. 2012;7(4):e36192.PubMedPubMedCentralCrossRef
102.
go back to reference van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374(1):33–42.PubMedCrossRef van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374(1):33–42.PubMedCrossRef
103.
go back to reference Oestereich L, Ludtke A, Wurr S, et al. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014;105:17–21.PubMedCrossRef Oestereich L, Ludtke A, Wurr S, et al. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014;105:17–21.PubMedCrossRef
108.
go back to reference Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010;375(9729):1896–905.PubMedCrossRef Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010;375(9729):1896–905.PubMedCrossRef
109.
go back to reference Dunning J, Sahr F, Rojek A, Gannon F, Carson G, Idriss B, Massaquoi T, Gandi R, Joseph S, Osman HK, Brooks TJ, Simpson AJ, Goodfellow I, Thorne L, Arias A, Merson L, Castle L, Howell-Jones R, Pardinaz-Solis R, Hope-Gill B, Ferri M, Grove J, Kowalski M, Stepniewska K, Lang T, Whitehead J, Olliaro P, Samai M, Horby PW; RAPIDE-TKM trial team. Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. PLoS Med. 2016 Apr 19;13(4):e1001997. doi:10.1371/journal.pmed.1001997. Dunning J, Sahr F, Rojek A, Gannon F, Carson G, Idriss B, Massaquoi T, Gandi R, Joseph S, Osman HK, Brooks TJ, Simpson AJ, Goodfellow I, Thorne L, Arias A, Merson L, Castle L, Howell-Jones R, Pardinaz-Solis R, Hope-Gill B, Ferri M, Grove J, Kowalski M, Stepniewska K, Lang T, Whitehead J, Olliaro P, Samai M, Horby PW; RAPIDE-TKM trial team. Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. PLoS Med. 2016 Apr 19;13(4):e1001997. doi:10.​1371/​journal.​pmed.​1001997.
110.
111.
go back to reference Goodman JL. Studying “secret serums”—toward safe, effective Ebola treatments. N Engl J Med. 2014;371(12):1086–9.PubMedCrossRef Goodman JL. Studying “secret serums”—toward safe, effective Ebola treatments. N Engl J Med. 2014;371(12):1086–9.PubMedCrossRef
112.
go back to reference Davey RTftM-NPIST, NIAID, NIH, Bethesda, MD, USA. PREVAIL II: a randomized controlled trial of ZMapp™ in acute Ebola virus infection. In: Conference on Retroviruses and Opportunistic Infections (CROI). Boston, Massachusetts, USA: IAS–USA/CROI Foundation; 2016. http://www.croiconference.org/sessions/prevail-ii-randomized-controlled-trial-zmapp™-acute-ebola-virus-infection. Accessed 23 Feb 2016. Davey RTftM-NPIST, NIAID, NIH, Bethesda, MD, USA. PREVAIL II: a randomized controlled trial of ZMapp™ in acute Ebola virus infection. In: Conference on Retroviruses and Opportunistic Infections (CROI). Boston, Massachusetts, USA: IAS–USA/CROI Foundation; 2016. http://​www.​croiconference.​org/​sessions/​prevail-ii-randomized-controlled-trial-zmapp™-acute-ebola-virus-infection.​ Accessed 23 Feb 2016.
113.
go back to reference Dodd LE, Proschan MA, Neuhaus J, Koopmeiners JS, Neaton J, Beigel JD, Barrett K, Lane HC, Davey RT Jr. Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study. J Infect Dis. 2016 Jun 15;213(12):1906–13. Dodd LE, Proschan MA, Neuhaus J, Koopmeiners JS, Neaton J, Beigel JD, Barrett K, Lane HC, Davey RT Jr. Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study. J Infect Dis. 2016 Jun 15;213(12):1906–13.
114.
go back to reference Gehring G, Rohrmann K, Atenchong N, et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother. 2014;69(8):2123–31.PubMedCrossRef Gehring G, Rohrmann K, Atenchong N, et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother. 2014;69(8):2123–31.PubMedCrossRef
115.
go back to reference Fedson DS, Jacobson JR, Rordam OM, et al. Treating the host response to Ebola virus disease with generic statins and angiotensin receptor blockers. MBio. 2015;6(3):e00716.PubMedPubMedCentralCrossRef Fedson DS, Jacobson JR, Rordam OM, et al. Treating the host response to Ebola virus disease with generic statins and angiotensin receptor blockers. MBio. 2015;6(3):e00716.PubMedPubMedCentralCrossRef
116.
go back to reference Gignoux E, Azman AS, de Smet M, et al. Effect of artesunate-amodiaquine on mortality related to Ebola virus disease. N Engl J Med. 2016;374(1):23–32.PubMedCrossRef Gignoux E, Azman AS, de Smet M, et al. Effect of artesunate-amodiaquine on mortality related to Ebola virus disease. N Engl J Med. 2016;374(1):23–32.PubMedCrossRef
117.
go back to reference Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20(10):1126–9.PubMed Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20(10):1126–9.PubMed
118.
go back to reference Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of Ebola virus. J Virol. 2009;83(14):7296–304.PubMedPubMedCentralCrossRef Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of Ebola virus. J Virol. 2009;83(14):7296–304.PubMedPubMedCentralCrossRef
119.
go back to reference Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe—preliminary report. N Engl J Med. 2016;374(17):1647–1660.PubMedCrossRef Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe—preliminary report. N Engl J Med. 2016;374(17):1647–1660.PubMedCrossRef
120.
go back to reference Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386(9996):857–66.PubMedCrossRef Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386(9996):857–66.PubMedCrossRef
121.
go back to reference De Santis O, Audran R, Pothin E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016;16(3):311–320.PubMedCrossRef De Santis O, Audran R, Pothin E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016;16(3):311–320.PubMedCrossRef
122.
go back to reference Sarwar UN, Costner P, Enama ME, Berkowitz N, Hu Z, Hendel CS, Sitar S, Plummer S, Mulangu S, Bailer RT, Koup RA, Mascola JR, Nabel GJ, Sullivan NJ, Graham BS, Ledgerwood JE; VRC 206 Study Team. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis. 2015;211(4):549–57. Sarwar UN, Costner P, Enama ME, Berkowitz N, Hu Z, Hendel CS, Sitar S, Plummer S, Mulangu S, Bailer RT, Koup RA, Mascola JR, Nabel GJ, Sullivan NJ, Graham BS, Ledgerwood JE; VRC 206 Study Team. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis. 2015;211(4):549–57.
123.
go back to reference Milligan ID, Gibani MM, Sewell R, et al. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. JAMA. 2016;315(15):1610–1623. Milligan ID, Gibani MM, Sewell R, et al. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. JAMA. 2016;315(15):1610–1623.
124.
go back to reference Wong KK, Davey RT Jr, Hewlett AL, Kraft CS, Mehta AK, Mulligan MJ, Beck A, Dorman W, Kratochvil CJ, Lai L, Palmore TN, Rogers S, Smith PW, Suffredini AF, Wolcott M, Ströher U, Uyeki TM. Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirus. Clin Infect Dis. 2016 Apr 26. pii: ciw256. [Epub ahead of print]. Wong KK, Davey RT Jr, Hewlett AL, Kraft CS, Mehta AK, Mulligan MJ, Beck A, Dorman W, Kratochvil CJ, Lai L, Palmore TN, Rogers S, Smith PW, Suffredini AF, Wolcott M, Ströher U, Uyeki TM. Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirus. Clin Infect Dis. 2016 Apr 26. pii: ciw256. [Epub ahead of print].
125.
go back to reference Jacobs M, Aarons E, Bhagani S, Buchanan R, Cropley I, Hopkins S, Lester R, Martin D, Marshall N, Mepham S, Warren S, Rodger A. Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers. Lancet Infect Dis. 2015;15(11):1300–4.PubMedCrossRef Jacobs M, Aarons E, Bhagani S, Buchanan R, Cropley I, Hopkins S, Lester R, Martin D, Marshall N, Mepham S, Warren S, Rodger A. Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers. Lancet Infect Dis. 2015;15(11):1300–4.PubMedCrossRef
126.
go back to reference Lai L, Davey R, Beck A, Xu Y, Suffredini AF, Palmore T, Kabbani S, Rogers S, Kobinger G, Alimonti J, Link CJ Jr, Rubinson L, Ströher U, Wolcott M, Dorman W, Uyeki TM, Feldmann H, Lane HC, Mulligan MJ. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. JAMA. 2015;313(12):1249–55. Lai L, Davey R, Beck A, Xu Y, Suffredini AF, Palmore T, Kabbani S, Rogers S, Kobinger G, Alimonti J, Link CJ Jr, Rubinson L, Ströher U, Wolcott M, Dorman W, Uyeki TM, Feldmann H, Lane HC, Mulligan MJ. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. JAMA. 2015;313(12):1249–55.
127.
go back to reference Nanyonga M, Saidu J, Ramsay A, et al. Sequelae of Ebola virus disease, Kenema District, Sierra Leone. Clin Infect Dis. 2016;62(1):125–6.PubMedCrossRef Nanyonga M, Saidu J, Ramsay A, et al. Sequelae of Ebola virus disease, Kenema District, Sierra Leone. Clin Infect Dis. 2016;62(1):125–6.PubMedCrossRef
128.
go back to reference Epstein L, Wong KK, Kallen AJ, et al. Post-Ebola signs and symptoms in U.S. survivors. N Engl J Med. 2015;373(25):2484–6.PubMedCrossRef Epstein L, Wong KK, Kallen AJ, et al. Post-Ebola signs and symptoms in U.S. survivors. N Engl J Med. 2015;373(25):2484–6.PubMedCrossRef
129.
go back to reference Qureshi AI, Chughtai M, Loua TO, et al. Study of Ebola virus disease survivors in Guinea. Clin Infect Dis. 2015;61(7):1035–42.PubMedCrossRef Qureshi AI, Chughtai M, Loua TO, et al. Study of Ebola virus disease survivors in Guinea. Clin Infect Dis. 2015;61(7):1035–42.PubMedCrossRef
130.
go back to reference Clark DV, Kibuuka H, Millard M, et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis. 2015;15(8):905–12.PubMedCrossRef Clark DV, Kibuuka H, Millard M, et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis. 2015;15(8):905–12.PubMedCrossRef
131.
go back to reference Mattia JG, Vandy MJ, Chang JC, et al. Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect Dis. 2016;16(3):331–338.PubMedCrossRef Mattia JG, Vandy MJ, Chang JC, et al. Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect Dis. 2016;16(3):331–338.PubMedCrossRef
132.
go back to reference Vetter P, Kaiser L, Schibler M, et al. Sequelae of Ebola virus disease: the emergency within the emergency. Lancet Infect Dis. 2016. doi:10.1016/S1473-3099(16)00077-3, http://www.sciencedirect.com/science/article/pii/S1473309916000773. Vetter P, Kaiser L, Schibler M, et al. Sequelae of Ebola virus disease: the emergency within the emergency. Lancet Infect Dis. 2016. doi:10.​1016/​S1473-3099(16)00077-3, http://​www.​sciencedirect.​com/​science/​article/​pii/​S147330991600077​3.​
133.
go back to reference Lee-Kwan SH, DeLuca N, Adams M, et al. Support services for survivors of ebola virus disease—Sierra Leone, 2014. MMWR Morb Mortal Wkly Rep. 2014;63(50):1205–6.PubMed Lee-Kwan SH, DeLuca N, Adams M, et al. Support services for survivors of ebola virus disease—Sierra Leone, 2014. MMWR Morb Mortal Wkly Rep. 2014;63(50):1205–6.PubMed
136.
go back to reference Schoepp RJ, Rossi CA, Khan SH, et al. Undiagnosed acute viral febrile illnesses. Sierra Leone Emerg Infect Dis. 2014;20(7):1176–82.PubMedCrossRef Schoepp RJ, Rossi CA, Khan SH, et al. Undiagnosed acute viral febrile illnesses. Sierra Leone Emerg Infect Dis. 2014;20(7):1176–82.PubMedCrossRef
Metadata
Title
Ebola virus disease and critical illness
Authors
Aleksandra Leligdowicz
William A. Fischer II
Timothy M. Uyeki
Thomas E. Fletcher
Neill K. J. Adhikari
Gina Portella
Francois Lamontagne
Christophe Clement
Shevin T. Jacob
Lewis Rubinson
Abel Vanderschuren
Jan Hajek
Srinivas Murthy
Mauricio Ferri
Ian Crozier
Elhadj Ibrahima
Marie-Claire Lamah
John S. Schieffelin
David Brett-Major
Daniel G. Bausch
Nikki Shindo
Adrienne K. Chan
Tim O’Dempsey
Sharmistha Mishra
Michael Jacobs
Stuart Dickson
G. Marshall Lyon III
Robert A. Fowler
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2016
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-016-1325-2

Other articles of this Issue 1/2016

Critical Care 1/2016 Go to the issue